Bristol-Myers reveals access plan for hep C drug daclatasvir

US Pharma major Bristol-Myers Squibb (NYSE: BMY) has recently revealed a commercial strategy for sales of its new direct-acting antiviral (DAA) hepatitis C drug daclatasvir – trade name Daklinza - in developing countries.

“As part of our company-wide commitment to increasing access to medicines for patient populations in need, we have initiated discussions with government health authorities and other stakeholders in a number of developing countries to facilitate access to daclatasvir. Bristol-Myers Squibb’s HCV developing world access approach will utilize tiered pricing, licensing agreements and working in collaboration with other stakeholders who share in our commitment to working toward the eradication of hepatitis C,” said Amadou Diarra, vice president, global policy and government affairs, at Bristol-Myers Squibb, in a press statement.

He continued: “Our tiered pricing model for daclatasvir will take into consideration several factors, including countries’ economic development and burden of disease, as well as the commitment of the government to holistically address hepatitis C, including treatment and care. The lowest pricing tier will apply to all low-income and least developed countries. In addition, in 90 countries, Bristol-Myers Squibb will work with licensed generic manufacturers to supply licensed versions of daclatasvir.”